Astellas Pharma (OTCMKTS:ALPMY) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Astellas Pharma (OTCMKTS:ALPMY) announced its quarterly earnings results on Wednesday. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06), Zacks reports. Astellas Pharma had a return on equity of 25.79% and a net margin of 16.01%. The business had revenue of $3.98 billion for the quarter, compared to analysts’ expectations of $3.79 billion.

Astellas Pharma Trading Down 0.7%

Astellas Pharma stock opened at $16.01 on Thursday. The company has a 50 day moving average price of $15.05 and a 200 day moving average price of $14.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. Astellas Pharma has a 52 week low of $10.64 and a 52 week high of $17.35. The firm has a market capitalization of $28.97 billion, a price-to-earnings ratio of 12.18 and a beta of 0.06.

Wall Street Analyst Weigh In

Separately, Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.

Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.